Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
7/15/26 Roche (RO) Gazyva for Membranous Nephropathy Subscribers Only Subscribers Only Subscribers Only
7/15/26 Roche (RO) Gazyva for Nephrotic Syndrome Subscribers Only Subscribers Only Subscribers Only
7/11/26 Novo Nordisk (NVO) Alhemo for Hemophilia A and B - General Clotting Products Subscribers Only Subscribers Only Subscribers Only
7/10/26 GSK (GSK) risvutatug rezetecan for Small Cell Lung Cancer (SCLC) Subscribers Only Subscribers Only Subscribers Only
7/9/26 Kailera (KLRA) ribupatide for Obesity Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
09/17/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update